Title |
Cholinesterase inhibitors for Alzheimer's disease
|
---|---|
Published in |
Cochrane database of systematic reviews, January 2006
|
DOI | 10.1002/14651858.cd005593 |
Pubmed ID | |
Authors |
Jacqueline S Birks |
Abstract |
Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). Despite the evidence from the clinical studies and the intervening clinical experience the debate on whether ChEIs are effective continues. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 7 | 20% |
Russia | 2 | 6% |
France | 1 | 3% |
Myanmar | 1 | 3% |
Kazakhstan | 1 | 3% |
Netherlands | 1 | 3% |
Samoa | 1 | 3% |
Canada | 1 | 3% |
United Kingdom | 1 | 3% |
Other | 1 | 3% |
Unknown | 18 | 51% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 27 | 77% |
Practitioners (doctors, other healthcare professionals) | 5 | 14% |
Scientists | 2 | 6% |
Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 8 | <1% |
United States | 6 | <1% |
Netherlands | 2 | <1% |
Italy | 2 | <1% |
Pakistan | 1 | <1% |
Ireland | 1 | <1% |
Switzerland | 1 | <1% |
Sweden | 1 | <1% |
Brazil | 1 | <1% |
Other | 5 | <1% |
Unknown | 1148 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 184 | 16% |
Student > Ph. D. Student | 149 | 13% |
Student > Master | 143 | 12% |
Researcher | 125 | 11% |
Student > Doctoral Student | 60 | 5% |
Other | 193 | 16% |
Unknown | 322 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 244 | 21% |
Agricultural and Biological Sciences | 102 | 9% |
Neuroscience | 92 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 66 | 6% |
Biochemistry, Genetics and Molecular Biology | 65 | 6% |
Other | 239 | 20% |
Unknown | 368 | 31% |